non-ischaemic dilated cardiomyopathy (NIDCM)There is current debate regarding the value of implantable cardioverter defibrillators (ICD) in patients with non-ischemic dilated cardiomyopathy (NIDCM). Previous studies (DEFINITE, SCD-HeFT) enrolled patients not treated with optimal medication according to ...
Therefore, the aim of this study was to assess the effects of PLV procedure on LV performance in a series of consecutive patients with nonischemic dilated cardiomyopathy. Materials and methods Study group The study group consisted of 22 consecutive adult patients who underwent PLV from October 1996...
predictor of cardiac dysfunction in DM patients. Also, given the involvement of KLF5 in diabetic cardiomyopathy, it is also relevant that, miR-145, and miR-375 target KLF5, thereby repressing its levels [224,225,226]. While the role of these miRNAs as potential circulatory biomarkers is yet ...
as observed in hypertrophic cardiomyopathy and aortic stenosis, respectively [35]. In the last 10 years, epicardial fat, located between the myocardium and the visceral layer of pericardium, has gained increased interest in
Patients with UA/NSTEMI with ongoing ischemic discomfort should receive sublingual NTG (0. 4 mg) every 5 min for a total of 3 doses, after which assessment should be made about the need for intravenous NTG, if not contraindicated. (Level of Evidence: C) 4 Intravenous NTG is indicated in...
Also, the relatively altered myocardium of diabetic patients (diabetic cardiomyopathy) may be more prone to ischemia-reperfusion injury than the myocardium of patients without diabetes.10 Finally, underutilization of evidence-based therapy after MI has been suggested to explain worse outcomes in patients...
With near-normal life expectancy, contemporary cardiac care faces multiple challenges of cardiovascular diseases, disorders specific to HIV/AIDS, and those related to aging and higher prevalence of traditional risk factors. Non-ischemic cardiovascular diseases are major components of cardiovascular morbidity...
The treatment of DMD cardiomyopathy is identical to the treatment of non-ischemic heart failure and consists of ACE-I, beta-blockers, and mineralocorticoid receptor antagonists. Guideline-directed medical therapy (GDMT) mitigates the progression of the disease and reduces mortality [16]. Silva et ...
known non-cardiovascular comorbidity with poor prognosis (life expectancy <2 years), 16. pregnancy, 17. known genetically determined cardiomyopathy, and 18. any type of adult congenital heart disease. At least 30 days after the index episode [15], all patients underwent conventional CCTA scan ...
treatments, the ability to walk may be already lost as teenager, requiring a wheelchair. Breathing difficulties and heart disease usually start by age 20 and the current life expectancy is around 30 years. There is no cure and a substantial unmet medical need to improve and prolong life in mu...